{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:10:40Z","timestamp":1792059040994,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["825806"],"award-info":[{"award-number":["825806"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/01728"],"award-info":[{"award-number":["PI18\/01728"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Solitary fibrous tumour (SFT) is a rare mesenchymal malignancy that lacks robust prognostic and predictive biomarkers. Interferon-stimulated gene 15 (ISG15) is a ubiquitin-like modifier, associated with tumour progression, and with poor survival of SFT patients, as previous published by our group. Here, we describe the role of ISG15 in the biology of this rare tumour.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>ISG15 expression was assessed by immunohistochemistry in tissue microarrays from SFT patients and tested for correlation with progression-free survival and overall survival (OS). The effects of ISG15 knockdown or induction were investigated for cancer stem cell (CSC) characteristics and for drug sensitivity in unique in vitro models of SFT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prognostic value of ISG15 for OS was validated at protein level in malignant SFT patients, prospectively treated with pazopanib and enrolled in GEIS-32 trial. In SFT in vitro models, ISG15 knockdown lead to a decrease in the expression of CSC-related genes, including <jats:italic>SOX2, NANOG, ALDH1A1, ABCB1 and ABCC1<\/jats:italic>. Likewise, ISG15 downregulation decreased the clonogenic\/ tumoursphere-forming ability of SFT cells, while enhancing apoptotic cell death after doxorubicin, pazopanib or trabectedin treatment in 3D cell cultures. The regulation of CSC-related genes by ISG15 was confirmed after inducing its expression with interferon-\u03b21; ISG15 induction upregulated 1.28- to 451-fold the expression of CSC-associated genes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ISG15 is a prognostic factor in malignant SFT, regulating the expression of CSC-related genes and CSCs maintenance.\u00a0Our results suggest that ISG15 could be a novel therapeutic target in SFT, which could improve the efficacy of the currently available treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00018-022-04454-4","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T18:02:49Z","timestamp":1658426569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["ISG15 as a prognostic biomarker in solitary fibrous tumour"],"prefix":"10.1007","volume":"79","author":[{"given":"Jose L.","family":"Mondaza-Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Lopez-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Sanchez-Bustos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Blanco-Alcaina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Castilla-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Collini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Merino-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Carrillo-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Maestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Hindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Garcia-Foncillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7350-6916","authenticated-orcid":false,"given":"Javier","family":"Martin-Broto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"4454_CR1","unstructured":"WHO (2020) Classification of Tumours Editorial B: Soft tissue and bone tumours. WHO"},{"key":"4454_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/ng.2522","volume":"45","author":"J Chmielecki","year":"2013","unstructured":"Chmielecki J, Crago AM, Rosenberg M, O\u2019Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA, Meyerson M (2013) Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 45:131\u2013132","journal-title":"Nat Genet"},{"key":"4454_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng.2509","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, Chen CL, Zhang L, Wang R, Su F et al (2013) Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45:180\u2013185","journal-title":"Nat Genet"},{"key":"4454_CR4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/gcc.22083","volume":"52","author":"A Mohajeri","year":"2013","unstructured":"Mohajeri A, Tayebwa J, Collin A, Nilsson J, Magnusson L, von Steyern FV, Brosj\u00f6 O, Domanski HA, Larsson O, Sciot R et al (2013) Comprehensive genetic analysis identifies a pathognomonic NAB2\/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer 52:873\u2013886","journal-title":"Genes Chromosomes Cancer"},{"key":"4454_CR5","volume-title":"WHO classification of tumours of soft tissue and bone","author":"CDM Fletcher","year":"2013","unstructured":"Fletcher CDM, International Agency for Research on C, Organizaci\u00f3n Mundial de la S (2013) WHO classification of tumours of soft tissue and bone. International Agency for Research on Cancer, Lyon"},{"key":"4454_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","volume":"20","author":"J Martin-Broto","year":"2019","unstructured":"Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS et al (2019) Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol 20:134\u2013144","journal-title":"Lancet Oncol"},{"key":"4454_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/S1470-2045(19)30826-5","volume":"21","author":"J Martin-Broto","year":"2020","unstructured":"Martin-Broto J, Cruz J, Penel N, Le Cesne A, Hindi N, Luna P, Moura DS, Bernabeu D, de Alava E, Lopez-Guerrero JA et al (2020) Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncol 21:456\u2013466","journal-title":"Lancet Oncol"},{"key":"4454_CR8","doi-asserted-by":"publisher","first-page":"14835","DOI":"10.1016\/S0021-9258(17)42679-2","volume":"259","author":"BD Korant","year":"1984","unstructured":"Korant BD, Blomstrom DC, Jonak GJ, Knight E Jr (1984) Interferon-induced proteins. Purification and characterization of a 15,000-dalton protein from human and bovine cells induced by interferon. J Biol Chem 259:14835\u201314839","journal-title":"J Biol Chem"},{"key":"4454_CR9","doi-asserted-by":"publisher","first-page":"11315","DOI":"10.1016\/S0021-9258(18)60961-5","volume":"262","author":"AL Haas","year":"1987","unstructured":"Haas AL, Ahrens P, Bright PM, Ankel H (1987) Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J Biol Chem 262:11315\u201311323","journal-title":"J Biol Chem"},{"key":"4454_CR10","doi-asserted-by":"publisher","first-page":"7806","DOI":"10.1016\/S0021-9258(18)42585-9","volume":"267","author":"KR Loeb","year":"1992","unstructured":"Loeb KR, Haas AL (1992) The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J Biol Chem 267:7806\u20137813","journal-title":"J Biol Chem"},{"key":"4454_CR11","doi-asserted-by":"publisher","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","volume":"95","author":"SD Der","year":"1998","unstructured":"Der SD, Zhou A, Williams BR, Silverman RH (1998) Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 95:15623\u201315628","journal-title":"Proc Natl Acad Sci USA"},{"key":"4454_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/emboj\/20.3.362","volume":"20","author":"W Yuan","year":"2001","unstructured":"Yuan W, Krug RM (2001) Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. Embo j 20:362\u2013371","journal-title":"Embo j"},{"key":"4454_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1089\/jir.2004.24.647","volume":"24","author":"M Liu","year":"2004","unstructured":"Liu M, Hummer BT, Li X, Hassel BA (2004) Camptothecin induces the ubiquitin-like protein, ISG15, and enhances ISG15 conjugation in response to interferon. J Interferon Cytokine Res 24:647\u2013654","journal-title":"J Interferon Cytokine Res"},{"key":"4454_CR14","doi-asserted-by":"publisher","first-page":"12513","DOI":"10.1038\/ncomms12513","volume":"7","author":"JH Park","year":"2016","unstructured":"Park JH, Yang SW, Park JM, Ka SH, Kim JH, Kong YY, Jeon YJ, Seol JH, Chung CH (2016) Positive feedback regulation of p53 transactivity by DNA damage-induced ISG15 modification. Nat Commun 7:12513","journal-title":"Nat Commun"},{"key":"4454_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.14348\/molcells.2017.0027","volume":"40","author":"YJ Jeon","year":"2017","unstructured":"Jeon YJ, Park JH, Chung CH (2017) Interferon-stimulated gene 15 in the control of cellular responses to genotoxic stress. Mol Cells 40:83\u201389","journal-title":"Mol Cells"},{"key":"4454_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.tcb.2015.08.010","volume":"26","author":"A Khaminets","year":"2016","unstructured":"Khaminets A, Behl C, Dikic I (2016) Ubiquitin-dependent and independent signals in selective autophagy. Trends Cell Biol 26:6\u201316","journal-title":"Trends Cell Biol"},{"key":"4454_CR17","doi-asserted-by":"publisher","first-page":"e00852","DOI":"10.1128\/mBio.00852-20","volume":"11","author":"J Bhushan","year":"2020","unstructured":"Bhushan J, Radke JB, Perng YC, McAllaster M, Lenschow DJ, Virgin HW, Sibley LD (2020) ISG15 connects autophagy and IFN-\u03b3-Dependent control of Toxoplasma gondii infection in human cells. mBio 11:e00852\u201320","journal-title":"mBio"},{"key":"4454_CR18","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/sj.bjc.6603099","volume":"94","author":"JB Andersen","year":"2006","unstructured":"Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF (2006) Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer 94:1465\u20131471","journal-title":"Br J Cancer"},{"key":"4454_CR19","doi-asserted-by":"publisher","first-page":"R58","DOI":"10.1186\/bcr2117","volume":"10","author":"N Bektas","year":"2008","unstructured":"Bektas N, Noetzel E, Veeck J, Press MF, Kristiansen G, Naami A, Hartmann A, Dimmler A, Beckmann MW, Kn\u00fcchel R et al (2008) The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res 10:R58","journal-title":"Breast Cancer Res"},{"key":"4454_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1258\/ebm.2011.011236","volume":"237","author":"SD Desai","year":"2012","unstructured":"Desai SD, Reed RE, Burks J, Wood LM, Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S, Sankar S (2012) ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood) 237:38\u201349","journal-title":"Exp Biol Med (Maywood)"},{"key":"4454_CR21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.7314\/APJCP.2013.14.2.1147","volume":"14","author":"RP Laljee","year":"2013","unstructured":"Laljee RP, Muddaiah S, Salagundi B, Cariappa PM, Indra AS, Sanjay V, Ramanathan A (2013) Interferon stimulated gene-ISG15 is a potential diagnostic biomarker in oral squamous cell carcinomas. Asian Pac J Cancer Prev 14:1147\u20131150","journal-title":"Asian Pac J Cancer Prev"},{"key":"4454_CR22","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/onc.2012.633","volume":"33","author":"J Burks","year":"2014","unstructured":"Burks J, Reed RE, Desai SD (2014) ISGylation governs the oncogenic function of Ki-Ras in breast cancer. Oncogene 33:794\u2013803","journal-title":"Oncogene"},{"key":"4454_CR23","doi-asserted-by":"publisher","first-page":"8429","DOI":"10.18632\/oncotarget.2316","volume":"5","author":"C Li","year":"2014","unstructured":"Li C, Wang J, Zhang H, Zhu M, Chen F, Hu Y, Liu H, Zhu H (2014) Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget 5:8429\u20138441","journal-title":"Oncotarget"},{"key":"4454_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-020-05955-1","volume":"185","author":"YA Kariri","year":"2021","unstructured":"Kariri YA, Alsaleem M, Joseph C, Alsaeed S, Aljohani A, Shiino S, Mohammed OJ, Toss MS, Green AR, Rakha EA (2021) The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer. Breast Cancer Res Treat 185:293\u2013305","journal-title":"Breast Cancer Res Treat"},{"key":"4454_CR25","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1038\/s41388-021-02017-8","volume":"40","author":"A Bolado-Carrancio","year":"2021","unstructured":"Bolado-Carrancio A, Lee M, Ewing A, Muir M, Macleod KG, Gallagher WM, Nguyen LK, Carragher NO, Semple CA, Brunton VG et al (2021) ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling. Oncogene 40:6235\u20136247","journal-title":"Oncogene"},{"key":"4454_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.544956","volume":"10","author":"YL Li","year":"2020","unstructured":"Li YL, Gao YL, Niu XL, Wu YT, Du YM, Tang MS, Li JY, Guan XH, Song B (2020) Identification of subtype-specific metastasis-related genetic signatures in sarcoma. Front Oncol 10:544956","journal-title":"Front Oncol"},{"key":"4454_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.bbamcr.2019.02.008","volume":"1866","author":"XY Li","year":"2019","unstructured":"Li XY, Yan J, Sun J, Li C, Jiang JY, Wang JM, Meng XN, Liang JJ, Wang HQ (2019) BAG3 deletion suppresses stem cell-like features of pancreatic ductal adenocarcinoma via translational suppression of ISG15. Biochim Biophys Acta Mol Cell Res 1866:819\u2013827","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"4454_CR28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41388-019-0992-2","volume":"39","author":"J Sun","year":"2020","unstructured":"Sun J, Yan J, Qiao HY, Zhao FY, Li C, Jiang JY, Liu BQ, Meng XN, Wang HQ (2020) Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation. Oncogene 39:546\u2013559","journal-title":"Oncogene"},{"key":"4454_CR29","doi-asserted-by":"publisher","first-page":"16910","DOI":"10.18632\/oncotarget.7626","volume":"7","author":"RH Chen","year":"2016","unstructured":"Chen RH, Du Y, Han P, Wang HB, Liang FY, Feng GK, Zhou AJ, Cai MY, Zhong Q, Zeng MS, Huang XM (2016) ISG15 predicts poor prognosis and promotes cancer stem cell phenotype in nasopharyngeal carcinoma. Oncotarget 7:16910\u201316922","journal-title":"Oncotarget"},{"key":"4454_CR30","doi-asserted-by":"publisher","first-page":"7309","DOI":"10.1158\/0008-5472.CAN-14-1354","volume":"74","author":"B Sainz Jr","year":"2014","unstructured":"Sainz B Jr, Mart\u00edn B, Tatari M, Heeschen C, Guerra S (2014) ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells. Cancer Res 74:7309\u20137320","journal-title":"Cancer Res"},{"key":"4454_CR31","doi-asserted-by":"publisher","first-page":"45015","DOI":"10.18632\/oncotarget.7523","volume":"7","author":"RD Spagnuolo","year":"2016","unstructured":"Spagnuolo RD, Brich S, Bozzi F, Conca E, Castelli C, Tazzari M, Maestro R, Brenca M, Gualeni AV, Gloghini A et al (2016) Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours. Oncotarget 7:45015\u201345026","journal-title":"Oncotarget"},{"key":"4454_CR32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1177\/2211068216652846","volume":"22","author":"S Kessel","year":"2017","unstructured":"Kessel S, Cribbes S, D\u00e9ry O, Kuksin D, Sincoff E, Qiu J, Chan LL (2017) High-throughput 3D tumor spheroid screening method for cancer drug discovery using celigo image cytometry. SLAS Technol 22:454\u2013465","journal-title":"SLAS Technol"},{"key":"4454_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1089\/adt.2015.655","volume":"13","author":"O Sirenko","year":"2015","unstructured":"Sirenko O, Mitlo T, Hesley J, Luke S, Owens W, Cromwell EF (2015) High-content assays for characterizing the viability and morphology of 3D cancer spheroid cultures. Assay Drug Dev Technol 13:402\u2013414","journal-title":"Assay Drug Dev Technol"},{"key":"4454_CR34","doi-asserted-by":"publisher","first-page":"11474","DOI":"10.18632\/aging.102548","volume":"11","author":"B Wan","year":"2019","unstructured":"Wan B, Liu B, Huang Y, Yu G, Lv C (2019) Prognostic value of immune-related genes in clear cell renal cell carcinoma. Aging (Albany NY) 11:11474\u201311489","journal-title":"Aging (Albany NY)"},{"key":"4454_CR35","doi-asserted-by":"crossref","unstructured":"Zuo D, Chen Y, Zhang X, Wang Z, Jiang W, Tang F, Cheng R, Sun Y, Sun L, Ren L, Liu R (2021) Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma. Cancer Biol Med","DOI":"10.20892\/j.issn.2095-3941.2020.0516"},{"key":"4454_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1046\/j.1365-2559.1998.00412.x","volume":"32","author":"T Yokoi","year":"1998","unstructured":"Yokoi T, Tsuzuki T, Yatabe Y, Suzuki M, Kurumaya H, Koshikawa T, Kuhara H, Kuroda M, Nakamura N, Nakatani Y, Kakudo K (1998) Solitary fibrous tumour: significance of p53 and CD34 immunoreactivity in its malignant transformation. Histopathology 32:423\u2013432","journal-title":"Histopathology"},{"key":"4454_CR37","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.3892\/ijo.2015.2975","volume":"46","author":"S Ouladan","year":"2015","unstructured":"Ouladan S, Trautmann M, Orouji E, Hartmann W, Huss S, B\u00fcttner R, Wardelmann E (2015) Differential diagnosis of solitary fibrous tumors: A study of 454 soft tissue tumors indicating the diagnostic value of nuclear STAT6 relocation and ALDH1 expression combined with in situ proximity ligation assay. Int J Oncol 46:2595\u20132605","journal-title":"Int J Oncol"},{"key":"4454_CR38","first-page":"13166","volume":"8","author":"Y Han","year":"2015","unstructured":"Han Y, Zhang Q, Yu X, Han X, Wang H, Xu Y, Qiu X, Jin F (2015) Immunohistochemical detection of STAT6, CD34, CD99 and BCL-2 for diagnosing solitary fibrous tumors\/hemangiopericytomas. Int J Clin Exp Pathol 8:13166\u201313175","journal-title":"Int J Clin Exp Pathol"},{"key":"4454_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/1066896916650257","volume":"25","author":"N Schneider","year":"2017","unstructured":"Schneider N, Hallin M, Thway K (2017) STAT6 loss in dedifferentiated solitary fibrous tumor. Int J Surg Pathol 25:58\u201360","journal-title":"Int J Surg Pathol"},{"key":"4454_CR40","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41418-020-0519-y","volume":"27","author":"E Kong","year":"2020","unstructured":"Kong E, Kim HD, Kim J (2020) Deleting key autophagy elongation proteins induces acquirement of tumor-associated phenotypes via ISG15. Cell Death Differ 27:2517\u20132530","journal-title":"Cell Death Differ"},{"key":"4454_CR41","doi-asserted-by":"publisher","first-page":"7122","DOI":"10.18632\/oncotarget.27390","volume":"10","author":"S Cheriyamundath","year":"2019","unstructured":"Cheriyamundath S, Basu S, Haase G, Doernberg H, Gavert N, Brabletz T, Ben-Ze\u2019ev A (2019) ISG15 induction is required during L1-mediated colon cancer progression and metastasis. Oncotarget 10:7122\u20137131","journal-title":"Oncotarget"},{"key":"4454_CR42","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/cells9061449","volume":"9","author":"P Mart\u00ednez-Delgado","year":"2020","unstructured":"Mart\u00ednez-Delgado P, Lacerenza S, Obrador-Hevia A, Lopez-Alvarez M, Mondaza-Hernandez JL, Blanco-Alcaina E, Sanchez-Bustos P, Hindi N, Moura DS, Martin-Broto J (2020) Cancer stem cells in soft-tissue sarcomas. Cells 9:1449","journal-title":"Cells"},{"key":"4454_CR43","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.3390\/cancers13122913","volume":"13","author":"J Martin-Broto","year":"2021","unstructured":"Martin-Broto J, Mondaza-Hernandez JL, Moura DS, Hindi N (2021) A comprehensive review on solitary fibrous tumor: new insights for new horizons. Cancers (Basel) 13:2913","journal-title":"Cancers (Basel)"},{"key":"4454_CR44","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1038\/s41467-020-16395-2","volume":"11","author":"S Alcal\u00e1","year":"2020","unstructured":"Alcal\u00e1 S, Sancho P, Martinelli P, Navarro D, Pedrero C, Mart\u00edn-Hijano L, Valle S, Earl J, Rodr\u00edguez-Serrano M, Ruiz-Ca\u00f1as L et al (2020) ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. Nat Commun 11:2682","journal-title":"Nat Commun"},{"key":"4454_CR45","first-page":"6008","volume":"18","author":"J Zhang","year":"2019","unstructured":"Zhang J, Zhang Y, Li Z, Wu H, Xun J, Feng H (2019) Bioinformatics analysis of Ewing\u2019s sarcoma: Seeking key candidate genes and pathways. Oncol Lett 18:6008\u20136016","journal-title":"Oncol Lett"},{"key":"4454_CR46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.bbrc.2017.07.098","volume":"491","author":"Z Du","year":"2017","unstructured":"Du Z, Cai C, Sims M, Boop FA, Davidoff AM, Pfeffer LM (2017) The effects of type I interferon on glioblastoma cancer stem cells. Biochem Biophys Res Commun 491:343\u2013348","journal-title":"Biochem Biophys Res Commun"},{"key":"4454_CR47","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1111\/jcmm.16503","volume":"25","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Wang J, Qiao H, Huyan L, Liu B, Li C, Jiang J, Zhao F, Wang H, Yan J (2021) ISG15 is downregulated by KLF12 and implicated in maintenance of cancer stem cell-like features in cisplatin-resistant ovarian cancer. J Cell Mol Med 25:4395\u20134407","journal-title":"J Cell Mol Med"},{"key":"4454_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1052935","volume":"4","author":"SD Desai","year":"2015","unstructured":"Desai SD (2015) ISG15: a double edged sword in cancer. Oncoimmunology 4:e1052935","journal-title":"Oncoimmunology"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04454-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-022-04454-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04454-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T20:11:36Z","timestamp":1666728696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-022-04454-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4454"],"URL":"https:\/\/doi.org\/10.1007\/s00018-022-04454-4","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.S.M. reports institutional research grants from PharmaMar, Eisai, Immix BioPharma and Novartis outside the submitted work; travel support from PharmaMar, Eisai, Celgene, Bayer and Pfizer. F.R. reports speaker, consultancy or advisory role fees from Roche, BMS, MSD, Merck, Novartis, AstraZeneca, Pfizer, Lilly, Amgen, Pierre-Fabre, Incyte, Daichii-Sankyo, Bayer and Janssen. NH reports grants, personal fees and non-support from PharmaMar, research grants from Eisai, Immix BioPharma and Novartis outside the submitted work and re-search funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Novartis, Blueprint, Nektar, Forma, Amgen and Daichii-Sankyo. J.M.-B. reports research grants from PharmaMar, Eisai, Immix BioPharma and Novartis outside the submitted work; honoraria for advisory board participation and expert testimony from PharmaMar, honoraria for advisory board participation from Eli Lilly and Company, Bayer and Eisai; and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Novartis, Blueprint, Nektar, Forma, Amgen and Daichii-Sankyo. All other authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patients enrolled in the trial (Clinical Trial.gov number NCT02066285, and the European Union Drug Regulating Authorities Clinical Trials, number EUDRACT 2013-005456-15) consented to participate in the translational study presented here and signed an informed consent. Procedures were performed in accordance with guidelines established by the hospitals\u2019 Ethics Committee, as well as in conformance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the GEIS-32 clinical trial (ClinicalTrials.gov number NCT02066285 and European Union Drug Regulating Authorities Clinical Trials (EUDRACT), number 2013-005456-15).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"434"}}